Amgen Cholesterol IP Suit Restarts As EPO Decision Looms

Law360, London (October 22, 2020, 7:23 PM BST) -- A London judge on Thursday lifted a stay on Amgen's suit to block a cholesterol drug from Sanofi-Aventis and Regeneron, releasing the defendants from an agreement to be bound by an imminent European Patent Office decision on the patents' validity.

High Court Judge Anthony Mann rejected arguments from Amgen Inc.'s counsel that a February 2017 court order that paused the proceedings prevented Sanofi and Regeneron from now having the stay removed simply by showing that a key deadline had passed.

Amgen's counsel maintained that the court needed to weigh the facts of the situation before making such a ruling in the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!